New data reveals Roche’s OCREVUS is highly effective for RRMS
Swiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read more
Neurology
Sunovion gets FDA nod for KYNMOBI™ as Parkinson’s Disease treatment
Sunovion has announced it has received approval from the FDA for KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the treatment of
Read more
Pfizer’s gene therapy promising for Duchenne muscular dystrophy (DMD)
Pfizer Inc. has revealed revised clinical Phase 1b results on PF-06939926, an investigational gene therapy to treat Duchenne muscular dystrophy
Read more
Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more
SPRAVATO™ Nasal Spray (esketamine) Licensed in EU for treatment-resistant MDD
Esketamine is used as a fast-acting nasal spray treating patients who have not reacted well to conventional antidepressants. It is used
Read more